Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies. Lenzilumab has potential for use in combination with CAR-T and with checkpoint inhibitors across a range of cancers. Our next product candidate, ifabotuzumab is in the clinic for a rare brain cancer and could have applicability in other solid tumors.
The company is planning to enroll more patients in its Phase 3 clinical trial to achieve further interim analysis for lenzilumab efficacy in treating coronavirus (COVID-19)
